Turkiye Klinikleri Journal of Dental Sciences

.: ORIGINAL RESEARCH
Kompozit Materyallerin Gingival Fibroblast Hücreleri Üzerindeki Sitotoksik Etkisinin İncelenmesi
Investigation of the Cytotoxic Effect of Composite Materials on Gingival Fibroblast Cells
Ali TAGHIZADEHGHALEHJOUGHIa, Elif OKb, Hakan KAMALAKa
aTıbbi Genetik ABD, Atatürk Üniversitesi Tıp Fakültesi, Erzurum, TÜRKİYE
bÇocuk Diş Hekimliği ABD, Fırat Üniversitesi Diş Hekimliği Fakültesi, Elazığ, TÜRKİYE
cRestoratif Diş Tedavisi ABD, Kahramanmaraş Sütçü İmam Üniversitesi Diş Hekimliği Fakültesi, Kahramanmaraş, TÜRKİYE
Turkiye Klinikleri J Dental Sci. 2019;25(3):310-8
doi: 10.5336/dentalsci.2018-63270
Article Language: TR
Full Text
ÖZET
 Amaç: Oral dokularla temas eden restoratif materyaller bu dokularda inflamatuar, alerjik, toksik, mutajenik ve karsinojenik reaksiyonlara neden olabilmektedirler. Bu nedenle biyouyumluluk restoratif materyallerde ön planda tutulması gereken bir faktördür. Bu çalışmada rezin içerikli dolgu materyallerinin, dişeti fibroblast kök hücrelerine sitotoksik etkilerinin 3-(4,5-dimetiltiyazol- 2-yl)-2,5-difeniltetrazolyum bromür (MTT) analizi ile değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmada, yeni nesil (bir adet bulk fill, bir adet supra-nanohibrid, iki adet nanohibrid, iki adet mikrohibrid) altı farklı kompozit materyal kullanıldı. Çalışma grupları; XF: X-tra Fill (Voco- Almanya), GA: G- ænial Posterior (GC Tokyo Japonya), ES: Estelite Sigma Quick (Tokuyama-Japonya), GO: Grandio (Voco-Almanya), AB: Arabesk (Voco-Almanya) ve PS: Polofil Supra (Voco-Almanya) olarak hazırlandı. Her materyal için örnek sayısı 12 olarak belirlendi (n=12). Örnekler teflon kalıplar kullanılarak hazırlandı. GFBCs'lerin 72 saat süreyle örneklerle teması sonucu hücre canlılık oranları MTT analiziyle değerlendirildi. Bulgular: Grupların hücre canlılık oranları (%) sırasıyla; PS>AB>GO>ES>XF>GA olarak saptanmıştır. Sonuç: Bir materyalin sitotoksisitesinde; materyalin yapısı, içerdiği (doldurucu) oranı, monomer tipi, doldurucu içeriği gibi faktörlerin bir bütün olarak etkili olduğu, trietilen glikol dimetakrilat, etilen glikol dimetakrilat monomer varlığının materyalin potansiyel toksisite olasılığını artıran monomerler olduğu, doldurucu içeriğine eklenen parçacıkların (Fluro-alüminosilikat partikülleri, iterium trifluoride parçacıkları vb.) sitotoksisiteyi etkileyebileceği sonucuna varılmıştır.

Anahtar Kelimeler: Kompozit rezin; kök hücre; hücre canlılığı; sitotoksisite; MTT analizi
ABSTRACT
 Objective: Restorative materials in contact with oral tissues may cause inflammatory, allergic, toxic, mutagenic and carcinogenic reactions in these tissues. Therefore, biocompatibility factor is a factor that must be kept in foreground in restorative materials. The aim of this study was to evaluate the cytotoxic effects of resin-containing filler materials on gingival fibroblast stem cells by 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) analysis. Material and Methods: Six different composite materials of the new generation (one bulk fill, one supra-nanohybrid, two nanohybrid, two micro-hybrid) were used in the study. The study groups were prepared as XF: X-tra Fill (Voco-Germany), GA: G-anial Posterior (GC Tokyo Japan), ES: Estelite Sigma Quick (Tokuyama-Japan), GO: Grandio (Voco-Germany), AB: Arabesque (Voco-Germany) and PS: Polofil Supra (Voco-Germany). The number of samples for each material was determined as 12 (n=12). Samples were prepared by using teflon molds, and cell viability rates were evaluated by MTT analysis as a result of contact of the GFBCs with the samples for 72 hours. Results: Cell viability rates of the groups were as follows; PS> AB> GO> ES> XF> GA. Conclusion: The structure of the material, the rate of the monomer, the type of monomer and the content of the filler are effective for the cytotoxicity of a material as a whole. The presence of triethylene glycol dimethacrylate and ethylene glycol dimethylacrylate monomers which increase the potential for toxicity of the material, and the contents of the filler (Fluroalumino silicate particles, iterium trifluoride particles, etc.) can affect the cytotoxicity.

Keywords: Composite resin; stem cell; cell viability; cytotoxicity; MTT assay
REFERENCES:
  1. St-Georges AJ, Sturdevant JR, Swift EJ Jr, Thompson JY. Fracture resistance of prepared teeth restored with bonded inlay restorations. J Prosthet Dent. 2003;89(6):551-7. [Crossref] 
  2. Unlu N, Cetin CA. [New developments in ingredient of composite resin materials: review]. Turkiye Klinikleri J Dental Sci. 2008;14(3):156-67.
  3. Babakhin AA, Volozhin AI, Dubova LV, Lebedenko IIu, Babakhina IuA, Zhuravleva AA, et al. [Histamine releasing activity of dental materials as the indicator of their biocompatibility]. Stomatologiia (Mosk). 2008;87(1):8-17.
  4. Gerzina TM, Hume WR. Effect of dentine on release of TEGDMA from resin composite in vitro. J Oral Rehabil. 1994;21(4):463-8. [Crossref]  [PubMed] 
  5. Ortengren U, Wellendorf H, Karlsson S, Ruyter IE. Water sorption and solubility of dental composites and identification of monomers released in an aqueous environment. J Oral Rehabil. 2001;28(12):1106-15. [Crossref]  [PubMed] 
  6. Geurtsen W, Leyhausen G. Chemical-biological interactions of the resin monomer triethyleneglycol-dimethacrylate (TEGDMA). J Dent Res. 2001;80(12):2046-50. [Crossref]  [PubMed] 
  7. Moharamzadeh K, Van Noort R, Brook IM, Scutt AM. HPLC analysis of components released from dental composites with different resin compositions using different extraction media. J Mater Sci Mater Med. 2007;18(1):133-7. [Crossref]  [PubMed] 
  8. Thonemann B, Schmalz G, Hiller KA, Schweikl H. Responses of L929 mouse fibroblasts, primary and immortalized bovine dental papilla-derived cell lines to dental resin components. Dent Mater. 2002;18(4):318-23. [Crossref] 
  9. Engelmann J, Leyhausen G, Leibfritz D, Geurtsen W. Metabolic effects of dental resin components in vitro detected by NMR spectroscopy. J Dent Res. 2001;80(3):869-75. [Crossref]  [PubMed] 
  10. Janke V, von Neuhoff N, Schlegelberger B, Leyhausen G, Geurtsen W. TEGDMA causes apoptosis in primary human gingival fibroblasts. J Dent Res. 2003;82(10):814-8. [Crossref]  [PubMed] 
  11. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009;16(8):1093-107. [Crossref]  [PubMed]  [PMC] 
  12. Niles AL, Moravec RA, Eric Hesselberth P, Scurria MA, Daily WJ, Riss TL. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal Biochem. 2007;366(2):197-206. [Crossref]  [PubMed] 
  13. Temple L, Kawabata TT, Munson AE, White KL Jr. Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide. Fundam Appl Toxicol. 1993;21(4):412-9. [Crossref]  [PubMed] 
  14. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods. 1993;160(1):81-8. [Crossref] 
  15. Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol. 2007;5(1):127-36. [Crossref]  [PubMed] 
  16. Mandecki W, Ardelt B, Coradetti T, Davidowitz H, AFlint JA, Huang Z, et al. Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays. Cytometry A. 2006;69(11):1097-105. [Crossref]  [PubMed] 
  17. Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett. 1985;24(2-3):119-24. [Crossref] 
  18. Feoktistova M, Geserick P, Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc. 2016;(4):pdb.prot087379. [Crossref]  [PubMed] 
  19. Mjor IA. A comparison of in vivo and in vitro methods for toxicity testing of dental materials. Int Endod J. 1980;13(3):139-42. [Crossref]  [PubMed] 
  20. Altman FP. Tetrazolium salts and formazans. Prog Histochem Cytochem. 1976;9(3):1-56. [Crossref] 
  21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63. [Crossref] 
  22. Shimmura H, Tanabe K, Habiro K, Abe R, Toma H. Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. Transplantation. 2006;82(2):175-9. [Crossref]  [PubMed] 
  23. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell Viability Assays, in Assay Guidance Manual; 2004. Online Book; 2013. https://www.ncbi.nlm.nih.gov/books/NBK144065/.
  24. Geurtsen W. Biocompatibility of resin-modified filling materials. Crit Rev Oral Biol Med. 2000;11(3):333-55. [Crossref]  [PubMed] 
  25. Ferracane JL, Condon JR. Rate of elution of leachable components from composite. Dent Mater. 1990;6(4):282-7. [Crossref] 
  26. Trichaiyapon V, Torrungruang K, Panitvisai P. Cytotoxicity of flowable resin composite on cultured human periodontal ligament cells compared with mineral trioxide aggregate. J Investig Clin Dent. 2012;3(3):215-20. [Crossref]  [PubMed] 
  27. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 1996;17(2):103-14. [Crossref] 
  28. Hume WR, Gerzina TM. Bioavailability of components of resin-based materials which are applied to teeth. Crit Rev Oral Biol Med. 1996;7(2):172-9. [Crossref] 
  29. Ferracane JL. Hygroscopic and hydrolytic effects in dental polymer networks. Dent Mater. 2006;22(3):211-22. [Crossref]  [PubMed] 
  30. Durner J, Spahl W, Zaspel J, Schweikl H, Hickel R, Reichl FX. Eluted substances from unpolymerized and polymerized dental restorative materials and their Nernst partition coefficient. Dent Mater. 2010;26(1):91-9. [Crossref]  [PubMed] 
  31. Bouillaguet S. Biological risks of resin-based materials to the dentin-pulp complex. Crit Rev Oral Biol Med. 2004;15(1):47-60. [Crossref]  [PubMed] 
  32. Schweikl H, Spagnuolo G, Schmalz G. Genetic and cellular toxicology of dental resin monomers. J Dent Res. 2006;85(10):870-7. [Crossref]  [PubMed] 
  33. Schedle A, Ortengren U, Eidler N, Gabauer M, Hensten A. Do adverse effects of dental materials exist? What are the consequences, and how can they be diagnosed and treated? Clin Oral Implants Res. 2007;18 Suppl 3:232-56. [Crossref]  [PubMed] 
  34. Anagnostou M, Chatzigianni E, Doucoudakis S, Potamianou A, Tesseromatis C. Biocompatibility of resin composites subcutaneously implanted in rats with experimentally induced arthritis. Dent Mater. 2009;25(7):863-7. [Crossref]  [PubMed] 
  35. Peumans M, Van Meerbeek B, Lambrechts P, Vanherle G, Quirynen M. The influence of direct composite additions for the correction of tooth form and/or position on periodontal health. A retrospective study. J Periodontol. 1998;69(4):422-7. [Crossref]  [PubMed] 
  36. Kamalak H, Canan AC, Altin S. The mechanical properties of nanohybrid and bulk fill posterior composites. Biomed Res. 2018;29:2179-86. [Crossref] 
  37. Franz A, Konig F, Anglmayer M, Rausch-Fan X, Gille G, Rausch WD, et al. Cytotoxic effects of packable and nonpackable dental composites. Dent Mater. 2003;19(5):382-92. [Crossref] 
  38. Yildirim-Bicer AZ, Ergun G, Egilmez F, Demirkoprulu H. In vitro cytotoxicity of indirect composite resins: effect of storing in artificial saliva. Indian J Dent Res. 2013;24(1):81-6. [Crossref]  [PubMed] 
  39. Caughman WF, Caughman GB, Shiflett RA, Rueggeberg F, Schuster GS. Correlation of cytotoxicity, filler loading and curing time of dental composites. Biomaterials. 1991;12(8):737-40. [Crossref] 
  40. Longo DL, Paula-Silva FW, Faccioli LH, Gaton-Hernandez PM, Queiroz AM, Silva LA. Cytotoxicity and cytokine expression induced by silorane and methacrylate-based composite resins. J Appl Oral Sci. 2016;24(4):338-43. [Crossref]  [PubMed]  [PMC] 
  41. Goncalves F, Campos LMP, Rodrigues-Junior EC, Costa FV, Marques PA, Francci CE, et al. A comparative study of bulk-fill composites: degree of conversion, post-gel shrinkage and cytotoxicity. Braz Oral Res. 2018;32:e17. [Crossref] 
  42. Banava S, Najibfard K, Garcia-Godoy F, Saghiri MA, Ghahremani MH, Ostad N. Impact of dilution and polymerization on cytotoxicity of dentin adhesives to human gingival fibroblasts: early exposure time. J Dent Res Dent Clin Dent Prospects. 2015;9(3):151-8. [Crossref]  [PubMed]  [PMC] 
  43. Ferracane JL. Elution of leachable components from composites. J Oral Rehabil. 1994;21(4):441-52. [Crossref]  [PubMed] 
  44. Tanaka K, Taira M, Shintani H, Wakasa K, Yamaki M. Residual monomers (TEGDMA and Bis-GMA) of a set visible-light-cured dental composite resin when immersed in water. J Oral Rehabil. 1991;18(4):353-62. [Crossref]  [PubMed] 
  45. Inoue K, Hayashi I. Residual monomer (Bis-GMA) of composite resins. J Oral Rehabil. 1982;9(6):493-7. [Crossref]  [PubMed] 
  46. Spahl W, Budzikiewicz H, Geurtsen W. Determination of leachable components from four commercial dental composites by gas and liquid chromatography/mass spectrometry. J Dent. 1998;26(2):137-45. [Crossref] 
  47. Yap AU, Han VT, Soh MS, Siow KS. Elution of leachable components from composites after LED and halogen light irradiation. Oper Dent. 2004;29(4):448-53.
  48. Schmalz G. Concepts in biocompatibility testing of dental restorative materials. Clin Oral Investig. 1997;1(4):154-62. [Crossref]  [PubMed] 
  49. Tabatabaee MH, Mahdavi H, Zandi S, Kharrazi MJ. HPLC analysis of eluted monomers from two composite resins cured with LED and halogen curing lights. J Biomed Mater Res B Appl Biomater. 2009;88(1):191-6. [Crossref]  [PubMed] 
  50. Attik N, Hallay F, Bois L, Brioude A, Grosgogeat B, Colon P. Mesoporous silica fillers and resin composition effect on dental composites cytocompatibility. Dent Mater. 2017;33(2):166-74. [Crossref]  [PubMed] 
  51. Kanjevac T, Milovanovic M, Volarevic V, Lukic ML, Arsenijevic N, Markovic D, et al. Cytotoxic effects of glass ionomer cements on human dental pulp stem cells correlate with fluoride release. Med Chem. 2012;8(1):40-5. [Crossref]  [PubMed] 
  52. Botsali MS, Kusgoz A, Altintas SH, Ulker HE, Tanriver M, Kilic S, et al. Residual HEMA and TEGDMA release and cytotoxicity evaluation of resin-modified glass ionomer cement and compomers cured with different light sources. ScientificWorld Journal. 2014;28:218295. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com